Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals. MarketWatch Nov 25, 2024, 3:43:00 PM. Cassava Sciences Shares Lower Premarket on $40 Million Penalty to ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug, ...

Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...

Cassava Sciences (NASDAQ: SAVA) has become a hot topic among traders and active market participants thanks to its recent surge in volatility, liquidity, and overall market performance. Over the ...

Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals MarketWatch Nov 25, 2024, 3:43:00 PM. Cassava Sciences Shares Lower Premarket on $40 Million Penalty to ...

Publishing their findings in Nature, the researchers found that every 1-degree Celsius increase in global mean surface ...